Back to top

Image: Bigstock

Hims & Hers Expands Platform-Led Access to Digital Healthcare

Read MoreHide Full Article

Key Takeaways

  • Hims & Hers scales digital care using a unified, data-driven platform that improves with every interaction.
  • HIMS adds weight loss and menopause care without rebuilding its core digital infrastructure.
  • Hims & Hers expands into labs, AI and new markets using the same scalable software and data infrastructure.

The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , built its growth strategy around a highly scalable, software-driven platform that becomes more powerful as usage expands. The company’s digital infrastructure connects consumers, licensed providers, fulfillment and diagnostics into a single system, allowing each interaction to improve personalization and efficiency. Management emphasizes that scale does not simply add volume; it strengthens data feedback loops that refine treatment recommendations, improve retention and support a growing mix of multi-condition and proactive care. This platform-centric approach has supported rapid subscriber growth while maintaining operating leverage, as technology and development investments increasingly translate into broader reach and deeper engagement.

Recent launches underscore how software and data enable expansion across new categories without rebuilding the core operating model. Weight loss, alongside low testosterone, menopause and perimenopause, and upcoming whole-body lab testing, is delivered through a unified digital workflow that combines at-home testing, ongoing provider support, and data-driven personalization. The planned rollout of comprehensive lab testing and the longevity specialty further extends this model, positioning data as the entry point for proactive and preventive health management rather than episodic treatment.

At the same time, Hims & Hers is reinforcing its platform with targeted investments in AI, data pipelines and vertically integrated infrastructure. Capital raised in 2025 is earmarked to deepen these capabilities, while international expansion into Europe and Canada leverages the same software backbone. Together, these developments highlight a strategy where scalable technology and data — not physical footprint — remain the primary engines of growth.

TDOC & AMWL’s Platform-Led Scaling of Virtual Care

Teladoc Health, Inc. (TDOC - Free Report) continues to emphasize scalability by anchoring growth in software, data integration and platform breadth. Teladoc Health positions its Prism care delivery platform as the backbone that unifies clinical workflows, real-time data and provider collaboration at scale. Recent enhancements to TDOC’s 24/7 Care expand the range of treatable conditions while leveraging integrated claims and health data to drive preventive action. Teladoc Health is further extending this model through AI-enabled Clarity monitoring, reinforcing how data-driven infrastructure supports scalable, system-wide virtual care.

American Well Corporation (AMWL - Free Report) , popularly known as Amwell, centers its scalability strategy on the Amwell Converge platform, designed as a single, cloud-based operating system for hybrid care. Amwell enables clients to activate new use cases — ranging from virtual nursing to automated care — on the same data architecture without incremental complexity. AMWL’s continued rollout of Converge across large enterprises, including its expanded work with the U.S. Defense Health Agency, highlights how Amwell scales efficiently through standardized software, embedded analytics, and an increasingly AI-powered platform that grows alongside client demand.

HIMS’ Price Performance, Valuation and Estimates

Shares of Hims & Hers have gained 12.7% over the past year, outperforming the industry’s decline of 2.7%.

Zacks Investment Research
Image Source: Zacks Investment Research

HIMS’ forward 12-month P/S of 2.6X is lower than the industry’s average of 4.7X and its three-year median of 2.7X. It carries a Value Score of C.

Zacks Investment Research
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.

Zacks Investment Research
Image Source: Zacks Investment Research

Hims & Hers currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Teladoc Health, Inc. (TDOC) - free report >>

American Well Corporation (AMWL) - free report >>

Hims & Hers Health, Inc. (HIMS) - free report >>

Published in